Intrathecal T Regulatory Cell Delivery for Multiple Sclerosis

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for multiple sclerosis (MS) do not effectively inhibit autoimmune destruction of neurons in the central nervous system, and existing therapies can impair the immune response against foreign antigens.

Innovation Solution

Administering CD3+CD4+CD25+CD127− T regulatory cells intrathecally to suppress autoimmune responses and maintain immune tolerance, while preserving the response to foreign antigens.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Object-affected harmful factors

If conventional therapies are used to treat multiple sclerosis, then autoimmune destruction of neurons is inhibited, but the immune response against foreign antigens is impaired

Engineering Contradiction:

Improveautoimmune destruction of neuronsVSAvoidimmune response against foreign antigens

Core Design Contradiction:

Object-affected harmful factorsVSReliability

Solution Approach 1:

The patent applies local quality by administering Tregs specifically to the central nervous system through intrathecal or intracerebroventricular injection, concentrating the immunosuppressive effect only in the affected area (CNS) while leaving the peripheral immune system intact and responsive to foreign antigens

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

The patent uses Tregs as intermediary cells that mediate immunosuppression locally in the CNS. These regulatory T cells act as a bridge to suppress autoimmune responses against myelin sheath without directly affecting the overall immune system's ability to respond to foreign pathogens

Inventive Principle:

Principle #24Intermediary (Mediator)

2Object-affected harmful factors

If Treg cells are administered systemically, then autoimmune suppression is achieved, but immune response to foreign antigens is compromised

Engineering Contradiction:

Improveautoimmune reactionsVSAvoidresponse to foreign and dangerous antigens

Core Design Contradiction:

Object-affected harmful factorsVSAdaptability or versatility

Solution Approach 1:

The invention achieves local quality by delivering Tregs directly to the CNS compartment through intrathecal or intracerebroventricular routes, ensuring that immunosuppression occurs only where needed (in the central nervous system) while preserving systemic immune adaptability and response to foreign antigens

Inventive Principle:

Principle #3Local quality

3Area of stationary object

If intravenous administration of Tregs is used, then treatment coverage is broad, but efficacy in reaching CNS targets is reduced

Engineering Contradiction:

Improvetreatment coverage areaVSAvoidtarget delivery precision to CNS

Core Design Contradiction:

Area of stationary objectVSManufacturing precision

Solution Approach 1:

The patent uses the cerebrospinal fluid as an intermediary medium to transport Tregs directly to the CNS. By injecting into the intrathecal or intracerebroventricular space, the cells are delivered through the CSF circulation system that naturally distributes them to target areas in the brain and spinal cord

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The invention changes the administration dimension from systemic (intravenous) to compartment-specific (intrathecal/intracerebroventricular). This dimensional shift in drug delivery approach allows direct access to the CNS compartment, bypassing the need for systemic circulation and achieving precise target delivery

Inventive Principle:

Principle #17Another dimension (Dimensionality change)

Data Source

PatentUS20260083664A1Intrathecal administration of t regulatory cells in the treatment of multiple sclerosis

Publication Date: 2026.03.26 GDANSKI UNIV MEDYCZNY

AI summary

The invention relates to the medicinal product consisting of CD3+CD4+CD25+CD127− T regulatory cells administered intrathecally in the treatment of multiple sclerosis.